[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:non-muscle-invasive-bladder-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":188,"states":189},"Non-Muscle Invasive Bladder Carcinoma",29,26,[8,16,23,29,36,42,48,54,61,67,74,80,86,91,97,103,109,115,121,127,133,138,144,150,156,162,168,175,182],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07579195","Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:13.282904Z","2026-07-19T19:36:05.075574Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05126472","Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment",[20],"Phase 1","2026-08-26T02:18:39.640967Z","2026-07-05T05:32:16.800369Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04752722","LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve",[12],"2026-08-26T02:16:45.157238Z","2026-07-05T05:32:16.796933Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06510374","Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer",[33],"Phase 3","2026-08-26T02:17:16.126291Z","2026-07-05T05:32:16.755423Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06929286","A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)",[33],"2026-08-26T02:19:19.975067Z","2026-07-05T05:32:16.702636Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07480356","Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer",[33],"2026-08-26T02:15:53.461103Z","2026-07-05T03:45:20.251398Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07566156","Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )",[33],"2026-08-26T02:15:38.131683Z","2026-05-13T02:55:06.731133Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT03945162","Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive\u002FIntolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients",[58],"Phase 2","2026-08-26T02:18:00.873391Z","2026-05-05T02:43:29.284935Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06319820","A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer",[33],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:29.030151Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":72,"content_modified":73},"NCT07474519","Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer",[71],"Phase 4","2026-08-26T02:17:39.857430Z","2026-05-05T02:43:28.707726Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT06995677","Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",[58],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:28.212310Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT06173349","PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer",[20],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:28.176723Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":40,"content_modified":90},"NCT06567743","Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC",[58],"2026-05-05T02:43:27.959967Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06971614","A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC",[58],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:27.400456Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06800963","ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG",[12],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:27.287388Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06503614","A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer",[58],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:27.263491Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06833073","A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011\u002FINTerpath-011)",[58],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:27.093372Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05710848","A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer",[12],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:26.851584Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06733363","A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer",[58],"2026-08-26T02:18:18.766496Z","2026-07-05T05:32:16.690365Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07309445","A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States",[],"2026-08-26T02:19:09.651016Z","2026-05-13T02:55:06.685198Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":65,"content_modified":137},"NCT07225127","Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2",[],"2026-05-13T02:55:06.677806Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT07144319","Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.658549Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT05982561","Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.397923Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT02660645","Blue Light Cystoscopy With Cysview® Registry",[],"2026-08-26T02:17:11.311767Z","2026-05-13T02:55:06.098250Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT07318051","Sample Collection for Ongoing Research and Product Evaluation Study",[],"2026-08-26T02:15:33.331531Z","2026-05-13T02:55:06.687247Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT05790850","Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)",[],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:29.163821Z",{"nct_id":169,"title":170,"phases":171,"status":172,"updated_at":173,"content_modified":174},"NCT07725796","A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC",[20],"NOT_YET_RECRUITING","2026-08-26T02:19:18.331180Z","2026-07-30T01:46:14.449226Z",{"nct_id":176,"title":177,"phases":178,"status":179,"updated_at":180,"content_modified":181},"NCT05316155","Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:03:17.533348Z","2026-05-05T02:43:29.330309Z",{"nct_id":183,"title":184,"phases":185,"status":179,"updated_at":186,"content_modified":187},"NCT05843448","IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer",[20],"2026-08-03T02:42:01.977337Z","2026-05-05T02:43:29.186411Z",[],[190,194,198,202,206,210,213,217,220,224,227,230,233,237,240,244,247,250,253,257,260,264,267,270],{"state":191,"count":192,"slug":193},"California",17,"california",{"state":195,"count":196,"slug":197},"New York",16,"new-york",{"state":199,"count":200,"slug":201},"Texas",15,"texas",{"state":203,"count":204,"slug":205},"South Carolina",13,"south-carolina",{"state":207,"count":208,"slug":209},"Florida",12,"florida",{"state":211,"count":208,"slug":212},"Ohio","ohio",{"state":214,"count":215,"slug":216},"Indiana",11,"indiana",{"state":218,"count":215,"slug":219},"Tennessee","tennessee",{"state":221,"count":222,"slug":223},"Illinois",10,"illinois",{"state":225,"count":222,"slug":226},"Missouri","missouri",{"state":228,"count":222,"slug":229},"New Jersey","new-jersey",{"state":231,"count":222,"slug":232},"Pennsylvania","pennsylvania",{"state":234,"count":235,"slug":236},"Arizona",9,"arizona",{"state":238,"count":235,"slug":239},"Arkansas","arkansas",{"state":241,"count":242,"slug":243},"Colorado",8,"colorado",{"state":245,"count":242,"slug":246},"Maryland","maryland",{"state":248,"count":242,"slug":249},"Virginia","virginia",{"state":251,"count":242,"slug":252},"Washington","washington",{"state":254,"count":255,"slug":256},"Massachusetts",7,"massachusetts",{"state":258,"count":255,"slug":259},"Michigan","michigan",{"state":261,"count":262,"slug":263},"Alabama",6,"alabama",{"state":265,"count":262,"slug":266},"Georgia","georgia",{"state":268,"count":262,"slug":269},"Kansas","kansas",{"state":271,"count":262,"slug":272},"North Carolina","north-carolina"]